Tonix製藥控股 TNXP 深 滬
已收盤 12-12 16:00:00 美东时间
19.28
-0.350
-1.78%
華盛通- 最 高20.56
- 今 開19.70
- 成交量 41.06万股
- 最 低 19.10
- 昨 收 19.63
- 總市值 36.03亿
- 52周最高 69.97
- 市盈率 靜 --
- 換手率 0.22%
- 52周最低 6.76
- 委 比 -25.00%
- 總股本 1.87亿
- 歷史最高 13440000000.00
- 量 比 0.81
- 振 幅 7.44%
- 歷史最低 15.00
- 每 手 1
- 風險率 11.64%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel
Tonix Pharmaceuticals has appointed Irina Ishak as General Counsel, effective December 8, 2025. With over 25 years of experience in corporate legal and strategic leadership in the life sciences industry, Ms. Ishak will lead Tonix’s legal, corporate governance, and compliance functions. Previously, she served as Senior Counsel at Lowenstein Sandler LLP, advising Tonix on financings, licensing, and strategic transactions. Ms. Ishak's deep expertise...
12-09 12:00
Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder
Tonix Pharmaceuticals has received FDA clearance for its IND application to advance TNX-102 SL, a sublingual tablet, into a pivotal Phase 2 HORIZON study for treating major depressive disorder (MDD) in adults. The study, scheduled to begin enrollment mid-2026, will evaluate TNX-102 SL as a first-line monotherapy in approximately 360 patients. TNX-102 SL targets disrupted sleep associated with depression, leveraging its unique pharmacological prof...
11-24 12:00
Tonix Pharma Amends Sales Agreement to Raise Capital
Tonix Pharma ( ($TNXP) ) just unveiled an announcement. On November 21, 2025, T...
11-22 06:19
Tonix Pharma Expands Share Repurchase Program
Tonix Pharma ( ($TNXP) ) has issued an announcement. On November 18, 2025, Toni...
11-19 06:48
Tonix Pharmaceuticals' TONMYATM Now Commercially Available Across U.S.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, announced today that TONMYATM (cyclobenzaprine HCl sublingual tablets) is now
11-17 20:10
Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment
TONMYA, a novel, non-opioid treatment for fibromyalgia, has become commercially available nationwide by prescription. As the first FDA-approved fibromyalgia treatment in over 15 years, TONMYA provides once-daily bedtime analgesic relief with reduced adverse effects. Clinical trials demonstrated significant pain reduction and overall symptom improvement. While generally well-tolerated, it carries risks such as oral sensory changes and interactions...
11-17 12:00
Tonix Pharmaceuticals Q3 EPS $(3.59) Misses $(3.58) Estimate, Sales $3.290M Beat $3.100M Estimate
Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(3.59) per share which missed the analyst consensus estimate of $(3.58) by 0.14 percent. This is a 84.17 percent increase over losses of $(22.68) per
11-11 05:34
Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference
Tonix Pharmaceuticals Holding Corp. announced that CEO Seth Lederman will present at the Stifel 2025 Healthcare Conference. The company, which markets Tonmya for fibromyalgia and other treatments, is developing candidates for CNS disorders, immunology, infectious diseases, and rare conditions. Tonmya was the first new FDA-approved fibromyalgia drug in over 15 years. A webcast of the presentation will be available on the company’s website, with a ...
11-06 12:00
Tonix Teams Up With Mass General To Test New Antibody For Kidney Transplant Patients
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully-integrated, commercial biotechnology company, today announced a collaboration with Massachusetts General Hospital (MGH), a founding
11-04 20:15
